Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 77 entries
Sorted by: Best Match Show Resources per page
What is an Allergist?: Reconciled Document Incorporating Member Society Comments, September 3, 2007.

The World Allergy Organization journal

Del Giacco S, Rosenwasser LJ, Crisci CD, Frew AJ, Kaliner MA, Lee BW, Guanghui L, Maspero J, Moon HB, Takemasa N, Potter PC, Singh AB, Valovirta E, Vervloet D, Warner JO, Henley K.
PMID: 23283298
World Allergy Organ J. 2008 Jan;1(1):19-20. doi: 10.1097/wox.0b013e3181651679.

No abstract available.

Cite
Del Giacco S, Rosenwasser LJ, Crisci CD, et al. What is an Allergist?: Reconciled Document Incorporating Member Society Comments, September 3, 2007. World Allergy Organ J. 2008;1(1):19-20doi: 10.1097/wox.0b013e3181651679.
Del Giacco, S., Rosenwasser, L. J., Crisci, C. D., Frew, A. J., Kaliner, M. A., Lee, B. W., Guanghui, L., Maspero, J., Moon, H. B., Takemasa, N., Potter, P. C., Singh, A. B., Valovirta, E., Vervloet, D., Warner, J. O., Henley, K. (2008). What is an Allergist?: Reconciled Document Incorporating Member Society Comments, September 3, 2007. The World Allergy Organization journal, 1(1), 19-20. https://doi.org/10.1097/wox.0b013e3181651679
Del Giacco, Sergio, et al. "What is an Allergist?: Reconciled Document Incorporating Member Society Comments, September 3, 2007." The World Allergy Organization journal vol. 1,1 (2008): 19-20. doi: https://doi.org/10.1097/wox.0b013e3181651679
Del Giacco S, Rosenwasser LJ, Crisci CD, Frew AJ, Kaliner MA, Lee BW, Guanghui L, Maspero J, Moon HB, Takemasa N, Potter PC, Singh AB, Valovirta E, Vervloet D, Warner JO, Henley K. What is an Allergist?: Reconciled Document Incorporating Member Society Comments, September 3, 2007. World Allergy Organ J. 2008 Jan;1(1):19-20. doi: 10.1097/wox.0b013e3181651679. PMID: 23283298; PMCID: PMC3650953.
Copy Download .nbib Format: NLM
Repeated Activation of a CS-US-Contingency Memory Results in Sustained Conditioned Responding.

Frontiers in psychology

Joos E, Vansteenwegen D, Vervliet B, Hermans D.
PMID: 23755034
Front Psychol. 2013 May 30;4:305. doi: 10.3389/fpsyg.2013.00305. eCollection 2013.

Individuals seem to differ in conditionability, i.e., the ease by which the contingent presentation of two stimuli will lead to a conditioned response. In contemporary learning theory, individual differences in the etiology and maintenance of anxiety disorders are, among...

Cite
Joos E, Vansteenwegen D, Vervliet B, et al. Repeated Activation of a CS-US-Contingency Memory Results in Sustained Conditioned Responding. Front Psychol. 2013;4:305doi: 10.3389/fpsyg.2013.00305.
Joos, E., Vansteenwegen, D., Vervliet, B., & Hermans, D. (2013). Repeated Activation of a CS-US-Contingency Memory Results in Sustained Conditioned Responding. Frontiers in psychology, 4305. https://doi.org/10.3389/fpsyg.2013.00305
Joos, Els, et al. "Repeated Activation of a CS-US-Contingency Memory Results in Sustained Conditioned Responding." Frontiers in psychology vol. 4 (2013): 305. doi: https://doi.org/10.3389/fpsyg.2013.00305
Joos E, Vansteenwegen D, Vervliet B, Hermans D. Repeated Activation of a CS-US-Contingency Memory Results in Sustained Conditioned Responding. Front Psychol. 2013 May 30;4:305. doi: 10.3389/fpsyg.2013.00305. eCollection 2013. PMID: 23755034; PMCID: PMC3667234.
Copy Download .nbib Format: NLM
High resolution far-infrared Fourier transform spectroscopy of radicals at the AILES beamline of SOLEIL synchrotron facility.

The Review of scientific instruments

Martin-Drumel MA, Pirali O, Balcon D, Bréchignac P, Roy P, Vervloet M.
PMID: 22128965
Rev Sci Instrum. 2011 Nov;82(11):113106. doi: 10.1063/1.3660809.

Experimental far-infrared (FIR) spectroscopy of transient species (unstable molecules, free radicals, and ions) has been limited so far in both emission and absorption (mainly by the low probability of spontaneous emission in that spectral range and the low brightness...

Cite
Martin-Drumel MA, Pirali O, Balcon D, et al. High resolution far-infrared Fourier transform spectroscopy of radicals at the AILES beamline of SOLEIL synchrotron facility. Rev Sci Instrum. 2011;82(11):113106doi: 10.1063/1.3660809.
Martin-Drumel, M. A., Pirali, O., Balcon, D., Bréchignac, P., Roy, P., & Vervloet, M. (2011). High resolution far-infrared Fourier transform spectroscopy of radicals at the AILES beamline of SOLEIL synchrotron facility. The Review of scientific instruments, 82(11), 113106. https://doi.org/10.1063/1.3660809
Martin-Drumel, M A, et al. "High resolution far-infrared Fourier transform spectroscopy of radicals at the AILES beamline of SOLEIL synchrotron facility." The Review of scientific instruments vol. 82,11 (2011): 113106. doi: https://doi.org/10.1063/1.3660809
Martin-Drumel MA, Pirali O, Balcon D, Bréchignac P, Roy P, Vervloet M. High resolution far-infrared Fourier transform spectroscopy of radicals at the AILES beamline of SOLEIL synchrotron facility. Rev Sci Instrum. 2011 Nov;82(11):113106. doi: 10.1063/1.3660809. PMID: 22128965.
Copy Download .nbib Format: NLM
A discrete choice experiment on preferences of patients with rheumatoid arthritis regarding disease-modifying antirheumatic drugs: the identification, refinement, and selection of attributes and levels.

Patient preference and adherence

Mathijssen EG, van Heuckelum M, van Dijk L, Vervloet M, Zonnenberg SM, Vriezekolk JE, van den Bemt BJ.
PMID: 30197505
Patient Prefer Adherence. 2018 Aug 22;12:1537-1555. doi: 10.2147/PPA.S170721. eCollection 2018.

OBJECTIVE: To comprehensively describe the identification, refinement, and selection of attributes and levels for a discrete choice experiment (DCE) on preferences of patients with rheumatoid arthritis (RA) regarding disease-modifying antirheumatic drugs (DMARDs).METHODS: A mixed-methods approach, consisting of three consecutive...

Cite
Mathijssen EG, van Heuckelum M, van Dijk L, et al. A discrete choice experiment on preferences of patients with rheumatoid arthritis regarding disease-modifying antirheumatic drugs: the identification, refinement, and selection of attributes and levels. Patient Prefer Adherence. 2018;12:1537-1555doi: 10.2147/PPA.S170721.
Mathijssen, E. G., van Heuckelum, M., van Dijk, L., Vervloet, M., Zonnenberg, S. M., Vriezekolk, J. E., & van den Bemt, B. J. (2018). A discrete choice experiment on preferences of patients with rheumatoid arthritis regarding disease-modifying antirheumatic drugs: the identification, refinement, and selection of attributes and levels. Patient preference and adherence, 121537-1555. https://doi.org/10.2147/PPA.S170721
Mathijssen, Elke Ge, et al. "A discrete choice experiment on preferences of patients with rheumatoid arthritis regarding disease-modifying antirheumatic drugs: the identification, refinement, and selection of attributes and levels." Patient preference and adherence vol. 12 (2018): 1537-1555. doi: https://doi.org/10.2147/PPA.S170721
Mathijssen EG, van Heuckelum M, van Dijk L, Vervloet M, Zonnenberg SM, Vriezekolk JE, van den Bemt BJ. A discrete choice experiment on preferences of patients with rheumatoid arthritis regarding disease-modifying antirheumatic drugs: the identification, refinement, and selection of attributes and levels. Patient Prefer Adherence. 2018 Aug 22;12:1537-1555. doi: 10.2147/PPA.S170721. eCollection 2018. PMID: 30197505; PMCID: PMC6112777.
Copy Download .nbib Format: NLM
Novel insights into parathyroid hormone: report of The Parathyroid Day in Chronic Kidney Disease.

Clinical kidney journal

Ureña-Torres PA, Vervloet M, Mazzaferro S, Oury F, Brandenburg V, Bover J, Cavalier E, Cohen-Solal M, Covic A, Drüeke TB, Hindié E, Evenepoel P, Frazão J, Goldsmith D, Kazama JJ, Cozzolino M, Massy ZA.
PMID: 30976408
Clin Kidney J. 2018 Jul 20;12(2):269-280. doi: 10.1093/ckj/sfy061. eCollection 2019 Apr.

Chronic kidney disease (CKD) is often associated with a mineral and bone disorder globally described as CKD-Mineral and Bone Disease (MBD), including renal osteodystrophy, the latter ranging from high bone turnover, as in case of secondary hyperparathyroidism (SHPT), to...

Cite
Ureña-Torres PA, Vervloet M, Mazzaferro S, et al. Novel insights into parathyroid hormone: report of The Parathyroid Day in Chronic Kidney Disease. Clin Kidney J. 2018;12(2):269-280doi: 10.1093/ckj/sfy061.
Ureña-Torres, P. A., Vervloet, M., Mazzaferro, S., Oury, F., Brandenburg, V., Bover, J., Cavalier, E., Cohen-Solal, M., Covic, A., Drüeke, T. B., Hindié, E., Evenepoel, P., Frazão, J., Goldsmith, D., Kazama, J. J., Cozzolino, M., Massy, Z. A. (2019). Novel insights into parathyroid hormone: report of The Parathyroid Day in Chronic Kidney Disease. Clinical kidney journal, 12(2), 269-280. https://doi.org/10.1093/ckj/sfy061
Ureña-Torres, Pablo A, et al. "Novel insights into parathyroid hormone: report of The Parathyroid Day in Chronic Kidney Disease." Clinical kidney journal vol. 12,2 (2019): 269-280. doi: https://doi.org/10.1093/ckj/sfy061
Ureña-Torres PA, Vervloet M, Mazzaferro S, Oury F, Brandenburg V, Bover J, Cavalier E, Cohen-Solal M, Covic A, Drüeke TB, Hindié E, Evenepoel P, Frazão J, Goldsmith D, Kazama JJ, Cozzolino M, Massy ZA. Novel insights into parathyroid hormone: report of The Parathyroid Day in Chronic Kidney Disease. Clin Kidney J. 2018 Jul 20;12(2):269-280. doi: 10.1093/ckj/sfy061. eCollection 2019 Apr. PMID: 30976408; PMCID: PMC6452197.
Copy Download .nbib Format: NLM
Beyond Extinction: Prolonged Conditioning and Repeated Threat Exposure Abolish Contextual Renewal of Fear-Potentiated Startle Discrimination but Leave Expectancy Ratings Intact.

Frontiers in psychiatry

Leer A, Haesen K, Vervliet B.
PMID: 29681867
Front Psychiatry. 2018 Apr 06;9:117. doi: 10.3389/fpsyt.2018.00117. eCollection 2018.

Extinction treatments decrease fear via repeated exposures to the conditioned stimulus (CS) and are associated with a return of fear. Alternatively, fear can be reduced via reductions in the perceived intensity of the unconditioned stimulus (US), e.g., through repeated...

Cite
Leer A, Haesen K, Vervliet B. Beyond Extinction: Prolonged Conditioning and Repeated Threat Exposure Abolish Contextual Renewal of Fear-Potentiated Startle Discrimination but Leave Expectancy Ratings Intact. Front Psychiatry. 2018;9:117doi: 10.3389/fpsyt.2018.00117.
Leer, A., Haesen, K., & Vervliet, B. (2018). Beyond Extinction: Prolonged Conditioning and Repeated Threat Exposure Abolish Contextual Renewal of Fear-Potentiated Startle Discrimination but Leave Expectancy Ratings Intact. Frontiers in psychiatry, 9117. https://doi.org/10.3389/fpsyt.2018.00117
Leer, Arne, et al. "Beyond Extinction: Prolonged Conditioning and Repeated Threat Exposure Abolish Contextual Renewal of Fear-Potentiated Startle Discrimination but Leave Expectancy Ratings Intact." Frontiers in psychiatry vol. 9 (2018): 117. doi: https://doi.org/10.3389/fpsyt.2018.00117
Leer A, Haesen K, Vervliet B. Beyond Extinction: Prolonged Conditioning and Repeated Threat Exposure Abolish Contextual Renewal of Fear-Potentiated Startle Discrimination but Leave Expectancy Ratings Intact. Front Psychiatry. 2018 Apr 06;9:117. doi: 10.3389/fpsyt.2018.00117. eCollection 2018. PMID: 29681867; PMCID: PMC5897540.
Copy Download .nbib Format: NLM
Effects of etelcalcetide on fibroblast growth factor 23 in patients with secondary hyperparathyroidism receiving hemodialysis.

Clinical kidney journal

Wolf M, Block GA, Chertow GM, Cooper K, Fouqueray B, Moe SM, Sun Y, Tomlin H, Vervloet M, Oberbauer R.
PMID: 32082556
Clin Kidney J. 2019 Apr 26;13(1):75-84. doi: 10.1093/ckj/sfz034. eCollection 2020 Feb.

BACKGROUND: Etelcalcetide is an intravenous calcimimetic approved for treatment of secondary hyperparathyroidism (sHPT) in patients receiving hemodialysis. Besides lowering parathyroid hormone (PTH), etelcalcetide also significantly reduces fibroblast growth factor 23 (FGF23), but the mechanisms are unknown.METHODS: To investigate potential...

Cite
Wolf M, Block GA, Chertow GM, et al. Effects of etelcalcetide on fibroblast growth factor 23 in patients with secondary hyperparathyroidism receiving hemodialysis. Clin Kidney J. 2019;13(1):75-84doi: 10.1093/ckj/sfz034.
Wolf, M., Block, G. A., Chertow, G. M., Cooper, K., Fouqueray, B., Moe, S. M., Sun, Y., Tomlin, H., Vervloet, M., & Oberbauer, R. (2020). Effects of etelcalcetide on fibroblast growth factor 23 in patients with secondary hyperparathyroidism receiving hemodialysis. Clinical kidney journal, 13(1), 75-84. https://doi.org/10.1093/ckj/sfz034
Wolf, Myles, et al. "Effects of etelcalcetide on fibroblast growth factor 23 in patients with secondary hyperparathyroidism receiving hemodialysis." Clinical kidney journal vol. 13,1 (2020): 75-84. doi: https://doi.org/10.1093/ckj/sfz034
Wolf M, Block GA, Chertow GM, Cooper K, Fouqueray B, Moe SM, Sun Y, Tomlin H, Vervloet M, Oberbauer R. Effects of etelcalcetide on fibroblast growth factor 23 in patients with secondary hyperparathyroidism receiving hemodialysis. Clin Kidney J. 2019 Apr 26;13(1):75-84. doi: 10.1093/ckj/sfz034. eCollection 2020 Feb. PMID: 32082556; PMCID: PMC7025329.
Copy Download .nbib Format: NLM
A Combined Analysis of Laser Optogalvanic and Fourier Transform Emission Spectra of NH2 near its Barrier to Linearity.

Journal of molecular spectroscopy

Destombes J, Hadj Bachir I, Huet TR, Vervloet M.
PMID: 9920709
J Mol Spectrosc. 1999 Feb;193(2):326-353. doi: 10.1006/jmsp.1998.7752.

The Ã2A1-&Xtilde;2B1 electronic transition of NH2 is reinvestigated in the region of its barrier to linearity. A detailed rotational analysis is performed on its laser optogalvanic spectrum recorded in the region 11 300-14 300 cm-1 and on its near...

Cite
Destombes J, Hadj Bachir I, Huet TR, et al. A Combined Analysis of Laser Optogalvanic and Fourier Transform Emission Spectra of NH2 near its Barrier to Linearity. J Mol Spectrosc. 1999;193(2):326-353doi: 10.1006/jmsp.1998.7752.
Destombes, J., Hadj Bachir I, Huet, T. R., & Vervloet, M. (1999). A Combined Analysis of Laser Optogalvanic and Fourier Transform Emission Spectra of NH2 near its Barrier to Linearity. Journal of molecular spectroscopy, 193(2), 326-353. https://doi.org/10.1006/jmsp.1998.7752
Destombes, et al. "A Combined Analysis of Laser Optogalvanic and Fourier Transform Emission Spectra of NH2 near its Barrier to Linearity." Journal of molecular spectroscopy vol. 193,2 (1999): 326-353. doi: https://doi.org/10.1006/jmsp.1998.7752
Destombes J, Hadj Bachir I, Huet TR, Vervloet M. A Combined Analysis of Laser Optogalvanic and Fourier Transform Emission Spectra of NH2 near its Barrier to Linearity. J Mol Spectrosc. 1999 Feb;193(2):326-353. doi: 10.1006/jmsp.1998.7752. PMID: 9920709.
Copy Download .nbib Format: NLM
Uniting the divergent Wolfram syndrome-linked proteins WFS1 and CISD2 as modulators of Ca.

Science signaling

Loncke J, Vervliet T, Parys JB, Kaasik A, Bultynck G.
PMID: 34582248
Sci Signal. 2021 Sep 28;14(702):eabc6165. doi: 10.1126/scisignal.abc6165. Epub 2021 Sep 28.

[Figure: see text].

Cite
Loncke J, Vervliet T, Parys JB, et al. Uniting the divergent Wolfram syndrome-linked proteins WFS1 and CISD2 as modulators of Ca. Sci Signal. 2021;14(702):eabc6165doi: 10.1126/scisignal.abc6165.
Loncke, J., Vervliet, T., Parys, J. B., Kaasik, A., & Bultynck, G. (2021). Uniting the divergent Wolfram syndrome-linked proteins WFS1 and CISD2 as modulators of Ca. Science signaling, 14(702), eabc6165. https://doi.org/10.1126/scisignal.abc6165
Loncke, Jens, et al. "Uniting the divergent Wolfram syndrome-linked proteins WFS1 and CISD2 as modulators of Ca." Science signaling vol. 14,702 (2021): eabc6165. doi: https://doi.org/10.1126/scisignal.abc6165
Loncke J, Vervliet T, Parys JB, Kaasik A, Bultynck G. Uniting the divergent Wolfram syndrome-linked proteins WFS1 and CISD2 as modulators of Ca. Sci Signal. 2021 Sep 28;14(702):eabc6165. doi: 10.1126/scisignal.abc6165. Epub 2021 Sep 28. PMID: 34582248.
Copy Download .nbib Format: NLM
Experimental models in psychopathology research: The relation between Research Domain Criteria and Experimental Psychopathology.

Current opinion in psychology

Lange I, Papalini S, Vervliet B.
PMID: 34418641
Curr Opin Psychol. 2021 Oct;41:118-123. doi: 10.1016/j.copsyc.2021.07.004. Epub 2021 Jul 19.

Experimental Psychopathology (EPP) and the Research Domain Criteria (RDoC) are research approaches that have developed in parallel, providing inter-related yet different scientific frameworks to investigate psychopathology at the intersection of fundamental and applied research. Here we address the overlap...

Cite
Lange I, Papalini S, Vervliet B. Experimental models in psychopathology research: The relation between Research Domain Criteria and Experimental Psychopathology. Curr Opin Psychol. 2021;41:118-123doi: 10.1016/j.copsyc.2021.07.004.
Lange, I., Papalini, S., & Vervliet, B. (2021). Experimental models in psychopathology research: The relation between Research Domain Criteria and Experimental Psychopathology. Current opinion in psychology, 41118-123. https://doi.org/10.1016/j.copsyc.2021.07.004
Lange, Iris, et al. "Experimental models in psychopathology research: The relation between Research Domain Criteria and Experimental Psychopathology." Current opinion in psychology vol. 41 (2021): 118-123. doi: https://doi.org/10.1016/j.copsyc.2021.07.004
Lange I, Papalini S, Vervliet B. Experimental models in psychopathology research: The relation between Research Domain Criteria and Experimental Psychopathology. Curr Opin Psychol. 2021 Oct;41:118-123. doi: 10.1016/j.copsyc.2021.07.004. Epub 2021 Jul 19. PMID: 34418641.
Copy Download .nbib Format: NLM
Erratum.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Bushinsky DA, Chertow GM, Cheng S, Deng H, Kopyt N, Martin KJ, Rastogi A, Ureña-Torres P, Vervloet M, Block GA.
PMID: 31093680
Nephrol Dial Transplant. 2019 May 15;1642. doi: 10.1093/ndt/gfz111. Epub 2019 May 15.

No abstract available.

Cite
Bushinsky DA, Chertow GM, Cheng S, et al. Erratum. Nephrol Dial Transplant. 2019;1642doi: 10.1093/ndt/gfz111.
Bushinsky, D. A., Chertow, G. M., Cheng, S., Deng, H., Kopyt, N., Martin, K. J., Rastogi, A., Ureña-Torres, P., Vervloet, M., & Block, G. A. (2019). Erratum. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 1642. https://doi.org/10.1093/ndt/gfz111
Bushinsky, David A, et al. "Erratum." Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association vol. (2019): 1642. doi: https://doi.org/10.1093/ndt/gfz111
Bushinsky DA, Chertow GM, Cheng S, Deng H, Kopyt N, Martin KJ, Rastogi A, Ureña-Torres P, Vervloet M, Block GA. Erratum. Nephrol Dial Transplant. 2019 May 15;1642. doi: 10.1093/ndt/gfz111. Epub 2019 May 15. PMID: 31093680; PMCID: PMC7473800.
Copy Download .nbib Format: NLM
Development and validation of a self-report measure of practical barriers to medication adherence: The medication practical barriers to adherence questionnaire (MPRAQ).

British journal of clinical pharmacology

Chan AHY, Vervloet M, Lycett H, Brabers A, van Dijk L, Horne R.
PMID: 33486802
Br J Clin Pharmacol. 2021 Nov;87(11):4197-4211. doi: 10.1111/bcp.14744. Epub 2021 Sep 10.

AIM: This study reports the development and validation of a new self-report measure, the Medication Practical barriers to Adherence Questionnaire (MPRAQ), which assesses practical barriers to medication adherence.METHODS: The MPRAQ comprises 15 statements describing practical barriers. Responses are scored...

Cite
Chan AHY, Vervloet M, Lycett H, et al. Development and validation of a self-report measure of practical barriers to medication adherence: The medication practical barriers to adherence questionnaire (MPRAQ). Br J Clin Pharmacol. 2021;87(11):4197-4211doi: 10.1111/bcp.14744.
Chan, A. H. Y., Vervloet, M., Lycett, H., Brabers, A., van Dijk, L., & Horne, R. (2021). Development and validation of a self-report measure of practical barriers to medication adherence: The medication practical barriers to adherence questionnaire (MPRAQ). British journal of clinical pharmacology, 87(11), 4197-4211. https://doi.org/10.1111/bcp.14744
Chan, Amy Hai Yan, et al. "Development and validation of a self-report measure of practical barriers to medication adherence: The medication practical barriers to adherence questionnaire (MPRAQ)." British journal of clinical pharmacology vol. 87,11 (2021): 4197-4211. doi: https://doi.org/10.1111/bcp.14744
Chan AHY, Vervloet M, Lycett H, Brabers A, van Dijk L, Horne R. Development and validation of a self-report measure of practical barriers to medication adherence: The medication practical barriers to adherence questionnaire (MPRAQ). Br J Clin Pharmacol. 2021 Nov;87(11):4197-4211. doi: 10.1111/bcp.14744. Epub 2021 Sep 10. PMID: 33486802.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 77 entries